ORIGINAL ARTICLE |
|
Year : 2017 | Volume
: 23
| Issue : 2 | Page : 117-122 |
|
Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?
Mahmoud M Mosli1, Moaiad Elyas2
1 Department of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia 2 Department of Gastroenterology and Hepatology, Saad Specialist Hospital, Al-Khobar, Kingdom of Saudi Arabia
Correspondence Address:
Mahmoud M Mosli Department of Medicine, King Abdulaziz University, Jeddah Kingdom of Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1319-3767.203362
|
|
Background/Aim: Intragastric balloon (IGB) is an effective and safe method of weight reduction. However, IGBs have been associated with a high rate of weight regain post removal. Accordingly, ways to improve sustained weight reduction including concomitant treatment with Glucagon-like peptide 1 (GLP-1) agonists have been proposed. This study aims to evaluate the effect of adding Liraglutide to IGB insertion on sustained weight reduction. Patients and Methods: A retrospective analysis of all cases treated with IGB with or without Liraglutide was performed. Outcomes were statistically compared. Results: A total of 108 patients were included; 64 were treated with IGB alone and 44 with IGB + Liraglutide. Six months after removing IGB, patients treated with IGB + Liraglutide had a higher mean weight loss post treatment completion (10.2 ± 6.7 vs. 18.5 ± 7.6, P = <0.0001) than those treated with IGB alone. After adjusting for covariates, patients treated with IGB alone demonstrated a higher mean body weight loss at the time of IGB removal (coefficient 7.71, 95% CI = 4.78–10.63), and a higher odds of treatment success 6 months post IGB removal (OR = 5.74, 95% CI = 1.79–188.42). Baseline body mass index appeared to be a significant predictor of mean body weight loss at the time of balloon removal. Conclusions: Adding Liraglutide to IGB does not appear to decrease the risk of weight regain 6 months post IGB removal. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|